Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has received a consensus recommendation of “Buy” from the ten research firms that are currently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $89.89.
ARWR has been the topic of several recent research reports. Chardan Capital reduced their price objective on Arrowhead Pharmaceuticals from $97.00 to $94.00 and set a “buy” rating on the stock in a research report on Friday, August 6th. HC Wainwright increased their price objective on Arrowhead Pharmaceuticals from $95.00 to $100.00 and gave the company a “buy” rating in a research report on Tuesday, August 10th. SVB Leerink increased their price objective on Arrowhead Pharmaceuticals from $44.00 to $45.00 and gave the company a “market perform” rating in a research report on Tuesday. Finally, TheStreet upgraded Arrowhead Pharmaceuticals from a “d+” rating to a “c-” rating in a research report on Thursday, November 4th.
In other news, CEO Christopher Richard Anzalone sold 50,000 shares of the firm’s stock in a transaction that occurred on Friday, October 22nd. The stock was sold at an average price of $65.63, for a total value of $3,281,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Adeoye Y. Olukotun sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, September 13th. The shares were sold at an average price of $63.76, for a total value of $318,800.00. The disclosure for this sale can be found here. Insiders have sold a total of 89,500 shares of company stock valued at $5,945,295 over the last 90 days. 3.50% of the stock is currently owned by company insiders.
NASDAQ ARWR traded up $3.15 during trading on Thursday, reaching $74.04. The company’s stock had a trading volume of 590,632 shares, compared to its average volume of 741,581. The stock has a market capitalization of $7.72 billion, a PE ratio of -60.20 and a beta of 1.14. The firm has a fifty day moving average of $67.29 and a 200 day moving average of $69.47. Arrowhead Pharmaceuticals has a one year low of $56.05 and a one year high of $93.66.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Sunday, November 21st. The biotechnology company reported ($0.61) EPS for the quarter, missing the consensus estimate of $0.04 by ($0.65). Arrowhead Pharmaceuticals had a negative net margin of 116.97% and a negative return on equity of 28.00%. During the same period in the prior year, the business earned ($0.48) EPS. As a group, equities analysts forecast that Arrowhead Pharmaceuticals will post -0.79 earnings per share for the current year.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc operates as a biopharmaceutical company. It develops medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R.
Recommended Story: Certificate of Deposit (CD)
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.